Completed PHASE2 NCT00186394

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma

Sponsor: National Institutes of Health (NIH)

Conditions Blood and Marrow Transplant (BMT) Lymphoma, Non-Hodgkin Lymphomas: Non-Hodgkin

Interventions ablative allogeneic hematopoietic cell transplantation

Updated 5 times since 2017 Last updated: Jul 23, 2010 Started: Apr 30, 2000 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

A PHASE2 clinical study on Blood and Marrow Transplant (BMT) and Lymphoma, Non-Hodgkin, this trial is completed. The trial is conducted by National Institutes of Health (NIH) and has accumulated 5 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institutes of Health (NIH)
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States